The Clonal Relationship Between the Ductal and Lobular Components of Mixed Ductal-Lobular Carcinomas Suggested a Ductal Origin in Most Tumors.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
26
7
2022
medline:
19
10
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
The relationship between the ductal and lobular components of invasive ductolobular carcinomas (IDLC) has not been fully elucidated. In this study, the molecular alterations of both components were analyzed in a series of 20 IDLC that were selected, not only by morphologic criteria, but also by the loss of E-cadherin expression in the lobular component. We found that 80% of tumors shared alterations of driver genes in both components, being PIK3CA the most common alteration. In addition, 45% of IDLC carried CDH1 mutations in their lobular component that were absent in the ductal component. Fluorescent in situ hybridization analysis of the CDH1 gene excluded homozygous CDH1 loss as a frequent cause of E-cadherin loss in tumors without CDH1 mutations. In addition, no pathogenic mutations of catenin genes were detected in this series of tumors. In 25% of tumors, actionable mutations in PIK3CA , AKT1 , and ERBB2 were found in only 1 component. Altogether, our results confirm that most IDLC derive from invasive carcinoma of no special type, in which a population of cells lose E-cadherin and acquire a lobular phenotype. The frequency of CDH1 mutations in IDLC appears to be lower than in conventional invasive lobular carcinomas, suggesting the implication of alternative mechanisms of E-cadherin loss. Moreover, molecular heterogeneity between ductal and lobular areas suggests the need for molecular characterization of both components to guide targeted therapies.
Identifiants
pubmed: 35877198
doi: 10.1097/PAS.0000000000001936
pii: 00000478-202211000-00010
pmc: PMC9561241
doi:
Substances chimiques
Cadherins
0
Catenins
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1545-1553Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
WHO Classification of Tumours [Editorial Board]. Organisation mondiale de la santé. Breast Tumours, 5th ed. Geneva: OMS; 2019.
McCart Reed AE, Kalinowski L, Simpson PT, et al. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res. 2021;23:6. doi:10.1186/s13058-020-01384-6
doi: 10.1186/s13058-020-01384-6
Christgen M, Cserni G, Floris G, et al. Lobular breast cancer: histomorphology and different concepts of a special spectrum of tumors. Cancers. 2021;13:3695. doi:10.3390/cancers13153695
doi: 10.3390/cancers13153695
Metzger-Filho O, Ferreira AR, Jeselsohn R, et al. Mixed invasive ductal and lobular carcinoma of the breast: prognosis and the importance of histologic grade. The Oncologist. 2019;24:e441–e449.
Ciriello G, Gatza ML, Beck AH, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163:506–519.
Tazaki E, Shishido‐Hara Y, Mizutani N, et al. Histopathological and clonal study of combined lobular and ductal carcinoma of the breast. Pathol Int. 2013;63:297–304.
McCart Reed AE, Kutasovic JR, Nones K, et al. Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology: mixed ductal-lobular tumours constitute a clonal entity. J Pathol. 2018;244:460–468.
Wagner PL, Kitabayashi N, Chen Y-T, et al. Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases. Am J Clin Pathol. 2009;132:871–876.
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142:1364–1382.
Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with Luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–750.
Rosa-Rosa J, Caniego-Casas T, Leskela S, et al. High frequency of ERBB2 activating mutations in invasive lobular breast carcinoma with pleomorphic features. Cancers. 2019;11:74. doi:10.3390/cancers11010074
doi: 10.3390/cancers11010074
Rosa-Rosa JM, Caniego-Casas T, Leskela S, et al. Modified SureSelectQXT target enrichment protocol for illumina multiplexed sequencing of FFPE samples. Biol Proced Online. 2018;20:19. doi:10.1186/s12575-018-0084-7
doi: 10.1186/s12575-018-0084-7
NovoAlign | Novocraft. Available at: http://www.novocraft.com/products/novoalign/ . Accessed March 31, 2022.
McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. Genome Biol. 2016;17:122. doi:10.1186/s13059-016-0974-4
doi: 10.1186/s13059-016-0974-4
González-Martínez S, Pizarro D, Pérez-Mies B, et al. Differences in the molecular profile between primary breast carcinomas and their cutaneous metastases. Cancers. 2022;14:1151. doi:10.3390/cancers14051151
doi: 10.3390/cancers14051151
Christgen M, Kandt LD, Antonopoulos W, et al. Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma. J Pathol CR. 2022;8:191–205.
Condorelli R, Mosele F, Verret B, et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2019;30:365–373.
McCart Reed AE, Foong S, Kutasovic JR, et al. The genomic landscape of lobular breast cancer. Cancers. 2021;13:1950. doi:10.3390/cancers13081950
doi: 10.3390/cancers13081950
Sarrió D, Moreno-Bueno G, Hardisson D, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability: E-Cadherin, Catenins and APC. Int J Cancer. 2003;106:208–215.
Roessler J, Ammerpohl O, Gutwein J, et al. The CpG island methylator phenotype in breast cancer is associated with the lobular subtype. Epigenomics. 2015;7:187–199.
de Groot JS, Ratze MA, van Amersfoort M, et al. αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer: αE-catenin is a candidate driver of invasive lobular carcinoma. J Pathol. 2018;245:456–467.